Incyte unveils positive results from Phase 2 ruxolitinib cream study
Category: #health  By Pankaj Singh  Date: 2019-10-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Incyte unveils positive results from Phase 2 ruxolitinib cream study

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continuously working towards finding a better treatment to cure this skin disease.

Incyte Corporation, a US based pharmaceutical firm headquartered in Delaware, reportedly announced the positive 52-week results from the company’s dose-ranging, double-blind and randomized, Phase 2 clinical trial evaluating ruxolitinib cream, an anti-inflammatory, nonsteroidal, JAK inhibitor treatment, in adults with vitiligo.

As announced by the firm earlier, the trial met its primary endpoint, showcasing that significantly more patients who were treated with ruxolitinib over a span of 24 weeks attained an improvement of ≥50% from baseline results in the F-VASI50 (facial vitiligo area severity index) score in comparison with the patients who were treated with a non-medicated cream. 

New results seen at week 52 demonstrate significant improvements in full body repigmentation when treated with ruxolitinib cream, calculated by the patient proportion achieving more than or equal to 50% improvement from the baseline in the total T-VASI50 (vitiligo area severity index), a vital secondary endpoint.     

Additionally, after the 52 week-long therapy with 1.5% ruxolitinib cream administered twice daily, 51% patients obtained a greater than or equal to 75% improvement (F-VASI75) and 58% patients achieved F-VASI50. After approximately 24 weeks, F-VASI75 is the primary measure of outcome of both TRuE-V2 and TRuE-V1 randomized Phase 3 clinical trials that are already under progress.

Group Vice President, Inflammation & Autoimmunity at Incyte, Jim Lee, M.D. stated that the company is very encouraged seeing the new positive data showcased at EADV, which demonstrates significant facial as well as total body repigmentation of the vitiligo lesions in patients who were treated by ruxolitinib cream, and continued enhancements with a treatment of longer duration.

Lee added that as the company seeks to provide a highly-needed option for the patients affected by this life changing disease, it is thrilled that pivotal Phase 3 trials which are evaluating ruxolitinib cream in patients with vitiligo are under progress, with their results predicted to be released in 2021.    

 

 

 

 

 

 

 

 

Source credit : https://investor.incyte.com/news-releases/news-release-details/incyte-announces-positive-52-week-results-randomized-phase-2



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

TikTok to donate 4 Lakh safety suits to Indian healthcare workers
TikTok to donate 4 Lakh safety suits to Indian healthcare workers
By Pankaj Singh

Amidst lowering availability of medical equipment and safety gear in India during the current COVID-19 crisis, Chinese video-sharing company, TikTok has made a generous gesture by announcing that it will donate ab...

Inzomelid declares positive CAPS treatment results, completes Phase I
Inzomelid declares positive CAPS treatment results, completes Phase I
By Pankaj Singh

Inflammasome biotech company Inflazome has reportedly announced the successful completion of Inzomelid’s Phase I clinical study. In addition, the firm has also declared that it has observed positive results from ...

Flipkart to re-open its online portal to deliver essential products
Flipkart to re-open its online portal to deliver essential products
By Pankaj Singh

Flipkart, a renowned Indian e-commerce company, reportedly announced that it would be re-starting its online portal to deliver essential commodities across India. The company had closed down all its operations on Wedne...